EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS‐AD‐linked degenerative phenotypes in the Dp16 mouse model of Down syndrome

Xu-Qiao Chen, Xinxin Zuo, Ann Becker, Michael Mante, Jazmin B Florio, Satish G Jadhav, Ricardo Albay, Aaron Johnstone, Dmitry Karachentsev, Robert Rissman, Hien Zhao, Steven F Dowdy und 1 weitere

Alzheimer's & Dementia · 2025-05 · 21 (5)

DOI: 10.1002/alz.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.05.2025. Verfasst von Xu-Qiao Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, rab5 GTP-Binding Proteins, Down Syndrome, Amyloid beta-Protein Precursor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Cure Alzheimer's Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Down syndrome (DS) markedly raises the risk of Alzheimer's disease (DS‐AD). Our findings identified widespread dysregulation of the endolysosomal network (ELN) in DS and DS‐AD brains, driven by increased APP gene dose, hyperactivation of RAB5, and elevated levels of guanine nucleotide exchange factors (GEFs) for RABs 7 and 11. METHODS We investigated whether increasing APP gene dose and RAB5 hyperactivation contributed to neuropathogenesis and whether a clinically feasible intervention could reverse ELN changes. The Dp16 DS‐AD mouse model was treated with a mouse App ‐specific antisense oligonucleotide ( App ‐ASO) and Rab5 ‐specific ASOs targeting Rab5a and Rab5b . RESULTS App ‐ASO treatment normalized full‐length APP (fl‐APP) and its products, RAB5 activity, and downstream RABs 7 and 11 pathways. Rab5 ‐ASOs reduced RAB5 levels and restored endosomal Rab activity. Both ASO treatments mitigated DS‐AD‐linked pathologies. DISCUSSION These findings highlight ELN dysregulation in DS and the therapeutic potential of ASO‐based strategies targeting APP or Rab5 to counteract DS‐AD features. Highlights App ‐ASO treatment reduced the levels of APP and its products and normalized endosomal Rab activity and GEF levels in Dp16 mice. Administration of Rab5 ‐ASOs reduced RAB5 levels and normalized endosomal Rab activity and GEF levels in Dp16 mice. Both ASO treatments were well tolerated and mitigated APP‐linked pathologies including tau hyperphosphorylation, neurotrophin signaling deficits, and synaptic protein loss. App ‐ASO or Rab5 ‐ASOs reversed established pathological phenotypes in Dp16 mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, Antisenserab5 GTP-Binding ProteinsDown SyndromeAmyloid beta-Protein PrecursorEndosomesrab GTP-Binding ProteinsAlzheimer DiseaseAnimalsDisease Models, AnimalMiceMice, TransgenicPhenotypeBrainHumans

Stichwörter der Autor:innen

Alzheimer's diseaseApp‐ASODown syndromeDp16 mouseRab5‐ASOendolysosomal networkneurotrophin signalingsynaptic proteinstau phosphorylation

Substanzen

Oligonucleotides, Antisenserab5 GTP-Binding ProteinsAmyloid beta-Protein Precursorrab GTP-Binding Proteins

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
  • Department of Cellular & Molecular Medicine, University of California San Diego, La Jolla, California, USA.
  • Ionis Pharmaceuticals Inc., Carlsbad, California, USA.

Förderung

  • NIH HHS
  • NIA NIH HHS
  • Cure Alzheimer's Fund
  • DH Chen Foundation
  • National Institutes of Health

Zitieren

APA

Chen, X. Q., Zuo, X., Becker, A., Mante, M., Florio, J. B., Jadhav, S. G., Albay, R., Johnstone, A., Karachentsev, D., Rissman, R., Zhao, H., Dowdy, S. F., & Mobley, W. C. (2025). Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS‐AD‐linked degenerative phenotypes in the Dp16 mouse model of Down syndrome. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.70022

Vancouver

Chen XQ, Zuo X, Becker A, Mante M, Florio JB, Jadhav SG, et al. Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS‐AD‐linked degenerative phenotypes in the Dp16 mouse model of Down syndrome. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.70022

BibTeX
@article{Chen2025,
  author = {Chen, Xu-Qiao and Zuo, Xinxin and Becker, Ann and Mante, Michael and Florio, Jazmin B and Jadhav, Satish G and Albay, Ricardo and Johnstone, Aaron and Karachentsev, Dmitry and Rissman, Robert and Zhao, Hien and Dowdy, Steven F and Mobley, William C},
  title = {Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS‐AD‐linked degenerative phenotypes in the Dp16 mouse model of Down syndrome},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {5},
  doi = {10.1002/alz.70022}
}
Kostenlos starten →